Mette Kjær
Keine laufenden Positionen mehr
Profil
Mette Kjær is the founder of Prophylix AS, which was founded in 2008.
She held the titles of COO, Director & Project Developer from 2012 to 2013.
Dr. Kjær also worked as a Principal at Universitetssykehuset Nord-Norge HF and St. Michaels Hospital (Toronto) Research Institute.
She received a doctorate degree from the University of Tromso in 2008.
Ehemalige bekannte Positionen von Mette Kjær
| Unternehmen | Position | Ende |
|---|---|---|
| St. Michaels Hospital (Toronto) Research Institute | Corporate Officer/Principal | - |
Universitetssykehuset Nord-Norge HF
 Universitetssykehuset Nord-Norge HF Medical/Nursing ServicesHealth Services Universitetssykehuset Nord-Norge HF provides health services. Its main tasks are patient care; training of patients and relatives; research; and education of health personnel. The company is headquartered in Oslo, Norway. | Corporate Officer/Principal | - |
Prophylix AS
 Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Gründer | - |
Ausbildung von Mette Kjær
| University of Tromso | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Universitetssykehuset Nord-Norge HF
Universitetssykehuset Nord-Norge HF Medical/Nursing ServicesHealth Services Universitetssykehuset Nord-Norge HF provides health services. Its main tasks are patient care; training of patients and relatives; research; and education of health personnel. The company is headquartered in Oslo, Norway. | Health Services |
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Health Technology |
| St. Michaels Hospital (Toronto) Research Institute |
